Nine new twin pairs with esophageal atresia: A review of the literature and performance of a twin study of the disorder. Biths Defects Res A Clin Mol Teratol [serie en Internet]. 2012 Mar [citado 19 de mayo de 2012];94(3). Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/...
Liu, L. (2013, November 19).Geographical prevalence and risk factors for pterygium: A systematic review and meta-analysis. National Library of Medicine. Retrieved March 26, 2024, fromhttps://pubmed.ncbi.nlm.nih.gov/24253031/
Spillover Effects From Basic Research on Drug Targets Santos et al40 cataloged 893 biological targets for FDA-approved products (1578) through June 2015, of which 1467 (93.0%) met inclusion criteria for this study. These products were associated with 515 biological targets, an average of 2.85 ...
Ischemic heart disease is one of the leading causes of mortality worldwide, and thus calls for development of more effective therapeutic strategies. This study aimed to identify potential therapeutic targets for coronary heart disease (CHD) and myocardia
Notably, the Final Rule does not require registration for Phase 1 trials of drugs and biological products, or feasibility studies of device products, unless funded by the NIH.[11] To provide more objective, structured criteria for evaluating whether study information must ...
Molecular tumor markers were unavailable for all datasets, and as a result classifications are based on the treating pathologist using the prevailing histologic criteria at time of diagnosis. The variant at 8q24.21 has been shown to have significant association with particular molecular subtypes, and ...
(grant no. 503176), the Wellcome Trust (grant no. 082604/2/07/Z) and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) (grant nos. 01GI0102, 01GI0711, 01GI0420). CHARGE was partly supported by the NIH/NIA grant R01 AG033193 and the NIA ...
An additional 5 trials were identified as potentially PI based on the manual Google search (Figure 1D and eTable 4 in the Supplement) but did not meet the formal criteria of inclusion within NCCN or FDA materials. With these studies included as PI, the overall rate of PI trials was 87 of...
Dr de Havenon reports NIH/NINDS funding (K23NS105924). Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit ...
their naming should become consistent as future versions of ProtNLM consume this data. Starting from UniProt release 2023_01, the criteria for showing ProtNLM names has changed to include an ensemble approach, an increased confidence threshold and an automatic corroboration pipeline (https://www.unip...